The official journal of the Korean Society for Neurorehabilitation (KSNR), and Asia-Oceanian Soceity for Neurorehabilitation (AOSNR)
pISSN 1976-8753 eISSN 2383-9910
Open Access, Peer-reviewed
Indexed in PubMed, PubMed Central, DOAJ and Korea Citation Index (KCI)
    Brain Neurorehabil. 2012 Sep;5(2):75-81. Korean.
    Published online Sep 26, 2012.
    https://doi.org/10.12786/bn.2012.5.2.75
    Copyright © 2012 Korean Society for Neurorehabilitation
    Original Article

    Efficacy and Safety of Solifenacin Succinate for Urinary Difficulty in Brain Lesion -Multicenter Prospective Study-

    Soo-Kyung Bok, M.D., Jun Ho Lim, M.D., Kang Hee Cho, M.D., Eun Seok Choi, M.D.,1 Sang Soo Kim, M.D.,1 Young Jin Lee, M.D.,2 and Noh Kyung Park, M.D.3
      • Department of Rehabilitation Medicine, School of Medicine, Chungnam National University, Korea.
      • 1Department of Rehabilitation Medicine, The Catholic University of Korea College of Medicine, Korea.
      • 2Department of Rehabilitation Medicine, Konyang University College of Medicine, Korea.
      • 3Department of Rehabilitation Medicine, Sun General Hospital, Korea.
    • Corresponding author (Email: ljh2434@cnuh.co.kr )
    Received February 22, 2012; Accepted July 18, 2012.

    Abstract

    Objective

    We studied the efficacy and safety of solifenacin for urinary difficulty in brain lesion from multicenter prospective study.

    Method

    Eighty patients with brain lesion who visited from 5 multicenter department of rehabilitation medicine from May 2009 to June 2010 were included. Patients were treated with solifenacin 5 mg to 10 mg for 12 weeks. The outcome measure was mean change in daily micturation frequency, daily frequency of incontinence, urgency episodes, and nocturia episodes from baseline to week 12. Patient's attitude to drug was assessed using the BSW Questionnaire (Benefit, Satisfaction and Willingness to Continue Questions).

    Results

    Sixty-one of 80 were evaluated for effect. All voiding parameters showed significant improvement after 12 weeks of treatment (p<0.05). There was no significant difference in efficacy of solifenacin between ischemic and hemorrhagic stroke. A twenty-two patients experienced 27 adverse events (AE). The most frequent AE were dry mouth (12.5%) and constipation (6.3%). Treatment related adverse events with solifenacin were mainly mild in severity, and only led to discontinuation in 6.3% of patients.

    Conclusion

    Solifenacin succinate improve urinary difficulty symptoms with acceptable efficacy and safety in patient with brain lesion.

    Keywords
    brain injuries; solifenacin succinat; urinary dysfunction

    Figures

    Fig. 1
    Changes of of urination after solifenacin (*p<0.001).

    Fig. 2
    Comparison of changes of urination according to stroke subtype.

    Tables

    Table 1
    Demographic and Clinical Features at Baseline

    Table 2
    Changes of Urination after Solifenacin

    Table 3
    Results of BSW Questionnaire

    Table 4
    Incidence Rates of Adverse Events after Solifenacin

    References

      1. Marinkovic S, Badlani G. Voiding and sexual dysfunction after cerebrovascular accidents. J Urol 2001;165:359–370.
      1. Gladman JR, Harwood DM, Barer DH. Predicting the outcome of acute stroke. prospective evaluation of five multivariate models and comparison with simple methods. J Neurol Neurosurg Psychiatry 1992;55:347–351.
      1. Nakayama H, Jørgensen HS, Pedersen PM, Raaschou HO, Olsen TS. Prevalence and risk factors of incontinence after stroke. The Copenhagen Stroke Study. Stroke 1997;28:58–62.
      1. Patel M, Coshall C, Rudd AG, Wolfe CD. Natural history and effects on 2-year outcomes of urinary incontinence after stroke. Stroke 2001;32:122–127.
      1. Taub NA, Wolfe CD, Richardson E, Burney PG. Predicting the disability of first-time stroke sufferers at 1 year. 12-month follow-up of a population-based cohort in southeast England. Stroke 1994;25:352–357.
      1. Brittain KR, Perry SI, Peet SM, Shaw C, Dallosso H, Assassa RP, Williams K, Jagger C, Potter JF, Castleden CM. Prevalence and impact of urinary symptoms among community dwelling stroke survivors. Stroke 2000;31:886–891.
      1. Chua K, Chuo A, Kong KH. Urinary incontinence after traumatic brain injury. Brain Inj 2003;17:469–478.
      1. Sakakibara R, Hattori T, Yasuda K, Yamanish T. Micturitional disturbance after acute hemispheric stroke: analysis of the lesion site by CT and MRI. J Neurol Sci 1996;137:47–56.
      1. Han JY, Choo MS. Drug treatment for lower urinary tract symptoms. J Korean Med Assoc 2011;54:637–645.
      1. Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464–470.
      1. Haab F, Cardozo L, Chapple C, Ridder AM. Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376–384.
      1. Michel MC, de la Rosette JJMCH. Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 2005;96:37–42.
      1. Pleil AM, Coyne KS, Reese PR, Jumadilova Z, Rovner ES, Kelleher CJ. The validation of patient-rated global assessments of treatment benefit, satisfaction, and willingness to continue--the BSW. Value Health 2005;8 Suppl 1:S25–S34.
      1. Cardozo L, Hessdorfer E, Milani R, Arano P, Dewilde L, Slack M, Drogendijk T, Wright M, Bolodeoku J. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008;102:1120–1127.
      1. Choo MS, Lee JZ, Lee JB, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG. Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract 2008;62:1675–1683.
      1. de Groat WC. A neurologic basis for the overactive bladder. Urology 1997;50:36–52.
      1. Sibley GN. The physiological response of the detrusor muscle to experimental bladder outflow obstruction in the pig. Br J Urol 1987;60:332–336.
    MeSH Terms
    Brain
    Brain Injuries
    Constipation
    Humans
    Mouth
    Nocturia
    Outcome Assessment (Health Care)
    Prospective Studies
    Quinuclidines
    Solifenacin Succinate
    Stroke
    Succinic Acid
    Surveys and Questionnaires
    Tetrahydroisoquinolines
    Metrics
    Share
    Figures
    slide
    slide

    1 / 2

    Tables
    slide
    slide
    slide
    slide

    1 / 4

    PERMALINK